DIOGENX
Updated 52 days ago
- Age: 4 years
- ID: 43310970/39
180 avenue du Prado 13008 Marseille
DiogenX is a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes. Founded in 2020 based on the research of leading type 1 (T1D) diabetes scientist Patrick Collombat on pancreatic beta cell regeneration, DiogenX is developing first-in-class recombinant proteins designed for the treatment of T1D...
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world...
DiogenX is supported by a network of world-leading experts in diabetes and a consortium of investors including diabetes and biopharma leaders Boehringer Ingelheim Venture Fund, Roche Venture Fund, Eli Lilly and Company, Omnes, JDRF T1D Fund and Adbio partners.